Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients

By |2021-09-14T16:56:52+01:00September 10th, 2021|News, Nityr|

Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer

By |2021-06-28T11:44:17+01:00June 28th, 2021|Corporate, News|

Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer

By |2021-05-25T17:41:24+01:00May 25th, 2021|Corporate, News|

Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors

By |2021-05-17T18:52:30+01:00April 29th, 2021|News, Nityr|

NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand

By |2021-05-17T18:52:30+01:00March 15th, 2021|News, Nityr|

Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department

By |2021-05-17T18:52:30+01:00December 2nd, 2020|Generics, News|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

By |2021-05-17T18:52:30+01:00October 19th, 2020|News, Nityr|

US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients

By |2021-05-17T18:52:30+01:00September 14th, 2020|Generics, News|

Dr David Buckeridge Joins Cycle Group Holdings’ Board of Directors

By |2021-05-17T18:52:31+01:00September 8th, 2020|Generics, News|

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

By |2021-05-17T18:52:31+01:00September 8th, 2020|Generics, News|
Go to Top